Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation

Autor: Yandi Xie, Minghui Li, Xiaojuan Ou, Sujun Zheng, Yinjie Gao, Xiaoyuan Xu, Ying Yang, Anlin Ma, Jia Li, Yuemin Nan, Huanwei Zheng, Juan Liu, Lai Wei, Bo Feng
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Druh dokumentu: article
ISSN: 1471-230X
DOI: 10.1186/s12876-023-02852-x
Popis: Abstract Background Since hepatitis B surface antigen (HBsAg) loss is rarely achieved with nucleos(t)ide analog (NA) treatment, most patients require life-long NA treatment. Previous studies have shown that some patients remain virologically responsive even after NA cessation. However, there is still controversy surrounding whether NA discontinuation increases the HBsAg loss rate. Therefore, this study aimed to assess the cumulative rate of HBsAg loss and identify the predictors of HBsAg loss after NA discontinuation. Methods This multicenter prospective study included HBV e antigen (HBeAg)-positive patients without cirrhosis from 12 hospitals in China who met the inclusion criteria. The enrolled patients stopped NA and were followed up with clinical and laboratory assessments every 3 months for 24 months after NA cessation or until clinical relapse (CR) occurred. Results Overall, 158 patients were classified into two groups. Group A included patients with HBsAg positivity at NA cessation (n = 139), and Group B included patients with HBsAg negativity at NA cessation (n = 19). In Group A, the 12-month and 24-month cumulative rates of HBsAg loss were4.3%and 9.4%, respectively. End of treatment (EOT) HBsAg (hazard ratio (HR) = 0.152, P
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje